文献速递结核与非结核分枝杆菌

Xpert MTB/RIF循环阈值作为结核病疾病严重度标志物:对结核治疗分层的意义

Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification.
PubMed 文献 · Clin Infect Dis · 2026-01-01

基于RIFASHORT治疗缩短非劣效试验数据,分析Xpert MTB/RIF半定量菌量与胸片病变范围组合定义的结核表型。广泛病变表型占四分之一人群但贡献过半复发,而有限病变表型中4个月1200mg利福平方案达到非劣效标准。

要点

  • Xpert半定量菌量联合胸片病变范围可区分复发与非复发。
  • 广泛病变表型占试验人群四分之一,占复发13/23。
  • 有限病变表型中4个月高剂量利福平方案达非劣效。

核心结论

  • derived的结核表型分类成功识别了四分之三的RIFASHORT参与者,其中4个月1200mg利福平方案非劣于6个月标准治疗。
  • 针对疾病分层的利福平基础结核治疗的确定性III期随机试验是合理的。

研究设计与样本

  • 分析RIFASHORT结核治疗缩短非劣效试验数据以定义结核表型分类。
  • RIFASHORT试验主要结局按方案定义的非劣效界值8个百分点重新分析,并按有限或广泛病变分层。

主要发现

  • Xpert MTB/RIF半定量细菌负荷联合胸片结核病变范围分级在复发与非复发间区分最强。
  • 广泛病变表型(高半定量细菌负荷且胸片广泛病变)占RIFASHORT试验人群四分之一,占治疗后复发13/23。
  • 有限病变表型(非高半定量细菌负荷或无胸片广泛病变)中,实验性4个月1200mg利福平方案在改良意向治疗分析(调整风险差:-1.3%;95%CI,-6.7%至4.0%)和符合方案分析(1.7%;95%CI,-3.8%至7.1%)均达到方案定义非劣效标准。

临床怎么用

  • 可依据Xpert半定量菌量联合胸片病变范围识别可能适合缩短至4个月高剂量利福平方案的有限病变结核患者。
  • 广泛病变表型患者复发风险高,可能需要更长疗程,不宜简单套用缩短方案。

局限性

  • 分析基于RIFASHORT试验数据,表型分类需外部验证。
  • 结论支持需开展确定性III期随机试验,当前证据尚不足以直接改变临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent trials have demonstrated that shortened 4-month treatment durations are effective for the majority of people with tuberculosis (TB). However, there is a population of patients with TB who require longer treatment durations. Prospectively identifying those who require shorter versus longer treatment durations would support evaluation and implementation of optimized regimens. METHODS: We analyzed data from the RIFASHORT TB treatment-shortening noninferiority trial to define a TB phenotype classification. The RIFASHORT trial primary outcome was reanalyzed using the protocol-defined noninferiority criterion of 8 percentage points, stratifying by those classified as having limited or extensive disease. RESULTS: Xpert MTB/RIF semiquantitative bacterial burden in combination with TB disease involvement grading on chest X-ray achieved the strongest differentiation between relapse and nonrelapse. The extensive disease TB phenotype (high semiquantitative bacterial burden and extensive TB disease on X-ray) accounted for one-quarter of the RIFASHORT trial population and more than half of all posttreatment TB relapses (13/23). For the limited TB disease phenotype (a semiquantitative bacterial burden other than high or no extensive TB disease on X-ray), the experimental 4-month 1200-mg rifampicin-containing regimen met the protocol-defined noninferiority criterion in both modified intention-to-treat (adjusted risk difference: -1.3%; 95% CI, -6.7% to 4.0%) and per protocol analyses (1.7%; 95% CI, -3.8% to 7.1%). CONCLUSIONS: The TB phenotype classification derived here successfully identified three-quarters of RIFASHORT trial participants for whom a 4-month 1200-mg rifampicin regimen was noninferior to the 6-month standard of care. A definitive phase III randomized trial of disease-stratified rifampicin-based TB treatment is justified.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Grint DJ, Dhillon J, Butcher PD, et al. Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification. Clin Infect Dis. 2026. PMID: 40991667. doi:10.1093/cid/ciaf527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。